ES2548214T3 - Variantes del factor de crecimiento de fibroblastos 21 - Google Patents

Variantes del factor de crecimiento de fibroblastos 21 Download PDF

Info

Publication number: ES2548214T3
Authority: ES; Spain
Prior art keywords: seq; growth factor; fibroblast growth; fgf21; pma
Prior art date: 2011-10-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES12766847.3T

Other languages

English (en)

Spanish (es)

Inventor

Craig Duane Dickinson

David Albert Driver

Ryan James Darling

Malgorzata Donata Gonciarz

Radmila Micanovic

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-04

Filing date

2012-09-25

Publication date

2015-10-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46964112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2548214(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-09-25 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2015-10-14 Application granted granted Critical

2015-10-14 Publication of ES2548214T3 publication Critical patent/ES2548214T3/es

Status Active legal-status Critical Current

2032-09-25 Anticipated expiration legal-status Critical

Links

102000018233 Fibroblast Growth Factor Human genes 0.000 title 1
108050007372 Fibroblast Growth Factor Proteins 0.000 title 1
229940126864 fibroblast growth factor Drugs 0.000 title 1
102000003973 Fibroblast growth factor 21 Human genes 0.000 abstract description 15
108090000376 Fibroblast growth factor 21 Proteins 0.000 abstract description 15
101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
102000056713 human FGF21 Human genes 0.000 abstract 1
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 21
235000019445 benzyl alcohol Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
102220475127 Ectodysplasin-A_L98D_mutation Human genes 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000013628 high molecular weight specie Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
241001515942 marmosets Species 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000000034 method Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

ES12766847.3T 2011-10-04 2012-09-25 Variantes del factor de crecimiento de fibroblastos 21 Active ES2548214T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161542906P	2011-10-04	2011-10-04
US201161542906P		2011-10-04
PCT/US2012/057053 WO2013052311A1 (en)	2011-10-04	2012-09-25	Fibroblast growth factor 21 variants

Publications (1)

Publication Number	Publication Date
ES2548214T3 true ES2548214T3 (es)	2015-10-14

Family

ID=46964112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES12766847.3T Active ES2548214T3 (es)	2011-10-04	2012-09-25	Variantes del factor de crecimiento de fibroblastos 21

Country Status (28)

Country	Link
US (2)	US8541369B2 (2)
EP (1)	EP2763689B1 (2)
JP (1)	JP6060167B2 (2)
KR (1)	KR20140059271A (2)
CN (1)	CN103906530B (2)
AP (1)	AP2014007532A0 (2)
AR (1)	AR087973A1 (2)
AU (1)	AU2012318956A1 (2)
BR (1)	BR112014007532A2 (2)
CA (1)	CA2843520A1 (2)
CL (1)	CL2014000801A1 (2)
CO (1)	CO6910165A2 (2)
CR (1)	CR20140142A (2)
DO (1)	DOP2014000050A (2)
EA (1)	EA201490521A1 (2)
EC (1)	ECSP14013285A (2)
ES (1)	ES2548214T3 (2)
IL (1)	IL230754A0 (2)
IN (1)	IN2014CN00782A (2)
MA (1)	MA35458B1 (2)
MX (1)	MX2014004159A (2)
PE (1)	PE20142044A1 (2)
PH (1)	PH12014500740A1 (2)
SG (1)	SG11201401792UA (2)
TN (1)	TN2014000096A1 (2)
TW (1)	TWI461435B (2)
WO (1)	WO2013052311A1 (2)
ZA (1)	ZA201400882B (2)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2682147C (en)	2007-03-30	2017-08-08	Ambrx, Inc.	Modified fgf-21 polypeptides and their uses
WO2013006486A2 (en)	2011-07-01	2013-01-10	Ngm Biopharmaceuticals, Inc.	Compositions, uses and methods for treatment of metabolic disorders and diseases
KR20150002801A (ko) *	2012-05-15	2015-01-07	일라이 릴리 앤드 캄파니	섬유모세포 성장 인자 21 단백질의 치료 용도
CA2871656A1 (en)	2012-06-11	2013-12-19	Eli Lilly And Company	Fibroblast growth factor 21 variants
TWI513705B (zh)	2012-06-11	2015-12-21	Lilly Co Eli	纖維母細胞生長因子２１蛋白質
US9290557B2 (en)	2012-11-28	2016-03-22	Ngm Biopharmaceuticals, Inc.	Compositions comprising variants and fusions of FGF19 polypeptides
HK1214832A1 (zh)	2012-11-28	2016-08-05	恩格姆生物制药公司	用於代謝病症和疾病治療的組合物和方法
US9273107B2 (en)	2012-12-27	2016-03-01	Ngm Biopharmaceuticals, Inc.	Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es)	2012-12-27	2025-03-14	Ngm Biopharmaceuticals Inc	Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
WO2015065897A1 (en)	2013-10-28	2015-05-07	Ngm Biopharmaceuticals, Inc.	Cancer models and associated methods
PT3097122T (pt)	2014-01-24	2020-07-21	Ngm Biopharmaceuticals Inc	Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
US20170065678A1 (en)	2014-03-11	2017-03-09	Novartis Ag	Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
US10398758B2 (en)	2014-05-28	2019-09-03	Ngm Biopharmaceuticals, Inc.	Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en)	2014-06-16	2015-12-23	Ngm Biopharmaceuticals, Inc.	Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN114129709A (zh)	2014-10-23	2022-03-04	恩格姆生物制药公司	包含肽变异体的药物组合物及其使用方法
SMT202100388T1 (it)	2014-10-24	2021-09-14	Bristol Myers Squibb Co	Polipeptidi fgf-21 modificati e loro usi
US10434144B2 (en)	2014-11-07	2019-10-08	Ngm Biopharmaceuticals, Inc.	Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en)	2015-07-29	2017-02-02	Ngm Biopharmaceuticals, Inc.	Binding proteins and methods of use thereof
JP6728352B2 (ja)	2015-11-09	2020-07-22	エヌジーエムバイオファーマシューティカルス，インコーポレーテッド	胆汁酸に関係した障害の治療方法
TW201731867A (zh) *	2015-12-02	2017-09-16	賽諾菲公司	Ｆｇｆ２１變異體
WO2017220706A1 (en) *	2016-06-22	2017-12-28	Novo Nordisk A/S	Pharmaceutical compositions of fgf21 derivatives and uses thereof
EP3503882A4 (en)	2016-08-26	2020-07-29	NGM Biopharmaceuticals, Inc.	METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CN106220724B (zh) *	2016-09-13	2019-10-11	河南师范大学	人成纤维细胞生长因子21重组蛋白及其制备方法和应用
CN106397607A (zh) *	2016-09-13	2017-02-15	河南师范大学	重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用
CN106432509B (zh) *	2016-09-13	2019-05-21	河南师范大学	一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用
EP4470551A3 (en)	2017-03-14	2025-02-26	Sunshine Lake Pharma Co., Ltd.	Dual-target fusion proteins comprising the fc portion of an immunoglobulin
MX2020002206A (es)	2017-09-08	2020-07-20	Bristol Myers Squibb Co	Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash).
US20200376080A1 (en)	2017-12-22	2020-12-03	Novartis Ag	Methods of treating metabolic disorders with fgf21 variants
AU2019218147B2 (en) *	2018-02-08	2023-06-08	Sunshine Lake Pharma Co., Ltd.	FGF21 variant, fusion protein and application thereof
CA3104686A1 (en) *	2018-07-03	2020-01-09	Bristol-Myers Squibb Company	Fgf-21 formulations
CN109836486B (zh) *	2019-01-30	2020-09-08	北京双因生物科技有限公司	成纤维生长因子21变体、其融合蛋白及其用途
CN111662373B (zh) *	2019-03-05	2024-05-14	广东东阳光药业股份有限公司	一种多肽分子及其应用
CN114853908B (zh)	2019-05-16	2024-06-07	浙江道尔生物科技有限公司	一种治疗代谢疾病的融合蛋白
IL294534A (en)	2020-01-08	2022-09-01	Bristol Myers Squibb Co	Fgf-21 conjugate formulations
CN115322794B (zh)	2020-01-11	2025-09-19	北京质肽生物医药科技有限公司	Glp-1和fgf21的融合蛋白的缀合物
JP2023538533A (ja)	2020-08-07	2023-09-08	ブリストル－マイヤーズスクイブカンパニー	線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
KR102495299B1 (ko) *	2020-11-03	2023-02-06	토드제약 주식회사	Fgf21의 열탄력성을 이용한 fgf21 생산 방법
US20240123031A1 (en)	2020-11-25	2024-04-18	Bristol-Myers Squibb Company	Methods of treating liver diseases
CA3224743A1 (en)	2021-07-14	2023-01-19	Beijing Ql Biopharmaceutical Co., Ltd.	Fusion polypeptides for metabolic disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US7459540B1 (en)	1999-09-07	2008-12-02	Amgen Inc.	Fibroblast growth factor-like polypeptides
WO2003011213A2 (en)	2001-07-30	2003-02-13	Eli Lilly And Company	Method for treating diabetes and obesity
CN1890371A (zh) *	2003-12-10	2007-01-03	伊莱利利公司	成纤维细胞生长因子的21突变蛋白
WO2006028714A1 (en)	2004-09-02	2006-03-16	Eli Lilly And Company	Muteins of fibroblast growth factor 21
EA011390B1 (ru) *	2004-09-02	2009-02-27	Эли Лилли Энд Компани	Мутантные белки (мутеины) фактора роста фибробластов 21
CA2682147C (en)	2007-03-30	2017-08-08	Ambrx, Inc.	Modified fgf-21 polypeptides and their uses
EP2296690B1 (en) *	2008-06-04	2016-11-30	Amgen, Inc	Fgf21 mutants and uses thereof
WO2010065439A1 (en) *	2008-12-05	2010-06-10	Eli Lilly And Company	Variants of fibroblast growth factor 21
EP2427207B1 (en)	2009-05-05	2017-08-16	Amgen, Inc	Fgf21 mutants and uses thereof
HRP20240135T1 (hr)	2009-05-05	2024-04-12	Amgen Inc.	Fgf21 mutanti i njihove upotrebe

2012
- 2012-09-20 AR ARP120103466A patent/AR087973A1/es unknown
- 2012-09-21 TW TW101134800A patent/TWI461435B/zh not_active IP Right Cessation
- 2012-09-25 ES ES12766847.3T patent/ES2548214T3/es active Active
- 2012-09-25 AU AU2012318956A patent/AU2012318956A1/en not_active Abandoned
- 2012-09-25 CN CN201280048530.2A patent/CN103906530B/zh not_active Expired - Fee Related
- 2012-09-25 EP EP12766847.3A patent/EP2763689B1/en active Active
- 2012-09-25 BR BR112014007532A patent/BR112014007532A2/pt not_active IP Right Cessation
- 2012-09-25 CA CA2843520A patent/CA2843520A1/en not_active Abandoned
- 2012-09-25 PH PH1/2014/500740A patent/PH12014500740A1/en unknown
- 2012-09-25 WO PCT/US2012/057053 patent/WO2013052311A1/en not_active Ceased
- 2012-09-25 IN IN782CHN2014 patent/IN2014CN00782A/en unknown
- 2012-09-25 PE PE2014000472A patent/PE20142044A1/es not_active Application Discontinuation
- 2012-09-25 JP JP2014534596A patent/JP6060167B2/ja active Active
- 2012-09-25 US US13/626,308 patent/US8541369B2/en active Active
- 2012-09-25 KR KR1020147008644A patent/KR20140059271A/ko not_active Withdrawn
- 2012-09-25 MX MX2014004159A patent/MX2014004159A/es unknown
- 2012-09-25 SG SG11201401792UA patent/SG11201401792UA/en unknown
- 2012-09-25 EA EA201490521A patent/EA201490521A1/ru unknown
- 2012-09-25 AP AP2014007532A patent/AP2014007532A0/xx unknown
2013
- 2013-08-13 US US13/965,243 patent/US8883726B2/en active Active
2014
- 2014-01-30 IL IL230754A patent/IL230754A0/en unknown
- 2014-02-05 ZA ZA2014/00882A patent/ZA201400882B/en unknown
- 2014-03-06 DO DO2014000050A patent/DOP2014000050A/es unknown
- 2014-03-06 TN TNP2014000096A patent/TN2014000096A1/en unknown
- 2014-03-17 CO CO14057034A patent/CO6910165A2/es unknown
- 2014-03-27 MA MA36861A patent/MA35458B1/fr unknown
- 2014-03-27 CR CR20140142A patent/CR20140142A/es unknown
- 2014-04-02 CL CL2014000801A patent/CL2014000801A1/es unknown
- 2014-04-04 EC ECSP14013285 patent/ECSP14013285A/es unknown

Also Published As

Publication number	Publication date
CA2843520A1 (en)	2013-04-11
EP2763689B1 (en)	2015-08-12
DOP2014000050A (es)	2014-04-15
AR087973A1 (es)	2014-04-30
ECSP14013285A (es)	2014-05-31
US8883726B2 (en)	2014-11-11
EP2763689A1 (en)	2014-08-13
SG11201401792UA (en)	2014-08-28
PH12014500740A1 (en)	2020-10-19
WO2013052311A1 (en)	2013-04-11
AP2014007532A0 (en)	2014-03-31
MA35458B1 (fr)	2014-09-01
US8541369B2 (en)	2013-09-24
BR112014007532A2 (pt)	2017-04-04
EA201490521A1 (ru)	2014-07-30
US20130324460A1 (en)	2013-12-05
IN2014CN00782A (2)	2015-04-03
ZA201400882B (en)	2016-02-24
AU2012318956A1 (en)	2014-02-06
KR20140059271A (ko)	2014-05-15
TWI461435B (zh)	2014-11-21
IL230754A0 (en)	2014-03-31
JP6060167B2 (ja)	2017-01-11
TN2014000096A1 (en)	2015-07-01
CL2014000801A1 (es)	2014-09-12
CR20140142A (es)	2014-05-02
JP2014530220A (ja)	2014-11-17
TW201326198A (zh)	2013-07-01
CN103906530A (zh)	2014-07-02
MX2014004159A (es)	2015-02-12
CN103906530B (zh)	2016-01-20
CO6910165A2 (es)	2014-03-31
PE20142044A1 (es)	2014-12-06
US20130085098A1 (en)	2013-04-04

Publication	Publication Date	Title
ES2548214T3 (es)	2015-10-14	Variantes del factor de crecimiento de fibroblastos 21
EP2749646B1 (en)	2018-03-21	IgG-BINDING PEPTIDE AND METHOD FOR DETECTING AND PURIFYING IgG USING SAME
Foser et al.	2003	Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS)
Pesek et al.	2008	Analysis of hydrophilic metabolites by high-performance liquid chromatography–mass spectrometry using a silica hydride-based stationary phase
ES2552636T3 (es)	2015-12-01	Insulina estabilizada por halógenos
AU2013254728B2 (en)	2018-04-12	Quantification of impurities for release testing of peptide products
EA201100180A1 (ru)	2011-10-31	Стабилизированный препарат антитела против а бета-пептида
Liu et al.	2011	Quantitation of a recombinant monoclonal antibody in monkey serum by liquid chromatography–mass spectrometry
CN102076707A (zh)	2011-05-25	无卡泊芬净杂质a的卡泊芬净
Zou et al.	2014	Human urine proteome: a powerful source for clinical research
CN102481336A (zh)	2012-05-30	从棘白菌素c0中分离和/或提纯棘白菌素b0
Lassen et al.	2011	A novel proteinaceous cytotoxin from the northern Scyphozoa Cyanea capillata (L.) with structural homology to cubozoan haemolysins
CN121253826A (zh)	2026-01-02	针对原发性免疫缺陷、胱氨酸病和威尔逊病的新生儿筛查
Marie et al.	2016	Characterization of conformers and dimers of antithrombin by capillary electrophoresis-quadrupole-time-of-flight mass spectrometry
CN110464842A (zh)	2019-11-19	包含抗pcsk9抗体的制剂及其用途
TW202003572A (zh)	2020-01-16	厄瑞努單抗組成物及其用途
KR102917813B1 (ko)	2026-01-26	수성 약학 제제
Wolf et al.	2004	Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography–mass spectrometry
CA2883176C (en)	2020-12-01	Composition comprising scirpusin a and scirpusin b and anti-obesity potential thereof
WO2002074245A2 (en)	2002-09-26	Anti-gpe antibodies, their uses, and analytical methods for gpe
EP4501345B1 (en)	2026-04-15	A composition comprising aflibercept and a variant thereof and related methods and uses
Hashempour et al.	2011	Analysis of cyclotides in Viola ignobilis by Nano liquid chromatography fourier transform mass spectrometry
EP4608862A1 (en)	2025-09-03	Compositions of anti-interleukin 12/interleukin 23 antibody
CN104311651A (zh)	2015-01-28	一种制备荧光单标记的眼镜蛇神经毒素的方法
Oudejans et al.	1990	In vitro biosynthesis of locust adipokinetic hormones: isolation and identification of the bioactive peptides and their prohormones